The International Contrast Ultrasound Society (ICUS)

FDA Approval of New Liver Imaging Agent in the US

Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., has announced  that LUMASON is now approved for use in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients.
 
LUMASON, known globally as SonoVue┬«, was approved by the FDA ion October 2014 for use in adults with suboptimal echocardiograms.  LUMASON is now the first ultrasound contrast agent to obtain FDA approval for use in liver imaging, to improve the sensitivity and specificity of ultrasonography for the differentiation between malignant and benign focal hepatic lesions. This approval also makes LUMASON the first ultrasound contrast agent approved for use in the pediatric population.
 
Click here for ICUS media release.

ICUS Sponsors

ICUS gratefully acknowledges its 2017 sponsors:

dentons-logo2

silver-level

Toshiba Medical logo resized

samsung-logo

siemens-new-original

philips-icus-logo

mindray

ICUS Tweets

Detect liver cancer effectively and more cheaply, without harmful radiation imaging or costly MRI eqpt. Read more: https://t.co/pxaHpwtAci
Lose weight while you sleep? Maybe soon! Read more at: https://t.co/TNRlXb4oDa
Follow Bubble Conference 2016 comment at #bubble2016

Contact ICUS

  • Address: 1900 K Street, N.W.
    Washington, DC 20006-1102, USA
  • Telephone: 202-408-6199

About ICUS

ICUS is the world’s only professional society exclusively devoted to contrast-enhanced ultrasound (CEUS) medical imaging technology.

Learn more...

You are here: Home ICUS News FDA Approval of New Liver Imaging Agent in the US